Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,084 recruiting studies in this area right now.
By phase
- Not applicable2,111
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California407
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,084 total
- NCT07628634RecruitingEarly Phase 1
Testing a Low-Methionine Diet in Solid Tumor Patients
This early-stage study explores whether eating a diet low in methionine (a natural amino acid found in protein) might help people with advanced solid tumors. Researchers will track how this dietary change affects blood levels and may improve treatment outcomes alongside standard cancer care.
Orange, CaliforniaAges 18 years+ - NCT07628738RecruitingPhase 2
Lower-dose radiation for early-stage NK/T-cell lymphoma after chemotherapy
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07628972RecruitingPhase 1
Quercetin for telomere biology disorders
This study tests whether a natural supplement called quercetin can help people with dyskeratosis congenita or other telomere biology disorders. These are rare conditions where cells have unusually short telomeres (protective caps on chromosomes), which can affect bone marrow and increase cancer risk.
Cincinnati, OhioAges 2 years+ - NCT07629596RecruitingEarly Phase 1
mRNA CAR-T therapy for severe lupus or autoimmune anemia
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT07632014Recruiting
Cancer Care Study for Young People Ages 0–21
This research study follows young people (babies through age 21) who have been diagnosed with cancer and are currently receiving treatment or in follow-up care. The study aims to better understand their care experiences and outcomes.
YerevanAges birth–21 years - NCT07633262Recruiting
Mobile app to help treat iron deficiency anemia in teen girls
This study tests a mobile phone app called FACE-APPS designed to help teenage girls improve their iron levels through better nutrition and iron supplementation. The goal is to see if the app can help increase iron in the blood and improve overall health in girls from underserved communities.
Wadi Addawasir, Wadi Addawasir GovernorateAges 14–14 - NCT07637084Recruiting
Light therapy for chronic pain and fatigue in Ehlers-Danlos Syndrome
This trial tests whether a non-invasive light therapy called photobiomodulation can reduce chronic pain and fatigue in people with hypermobile Ehlers-Danlos Syndrome (hEDS), a genetic condition affecting connective tissue. The light is applied to the skin and may help cells produce energy and reduce inflammation.
Boulogne-Billancourt, Île-de-France RegionAges 18 years+ - NCT07638007Recruiting
How targeted therapy affects thinking and memory in blood cancer
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
Rochester, New YorkAges 18 years+ - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+ - NCT07640893RecruitingPhase 2
Testing a new injection for von Willebrand disease
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
ChangshaAges 18–65 - NCT07642362Recruiting
Digital Support to Improve Quality of Life in Multiple Myeloma
This trial tests a digital app designed to help people with multiple myeloma (a blood cancer) manage their quality of life and symptoms. The study wants to see if using this app on a phone or computer can help patients feel better and stay connected to their care.
AthensAges Any age - NCT07643896Recruiting
Blood test for pregnancy risk assessment using fetal cells
This study tests a new blood test that looks for fetal cells in your bloodstream to check your baby's health during pregnancy. The test is non-invasive—just a regular blood draw—and aims to help identify pregnancy risks earlier than traditional methods.
Phoenix, ArizonaAges Any age - NCT07644832RecruitingPhase 1/Phase 2
New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
ChangshaAges 18–65 - NCT07649213Recruiting
Finding genetic causes of inherited hemolytic anemia
This research study helps doctors identify the genetic reason why some people have hemolytic anemia (a condition where red blood cells break down too quickly). Researchers will study patients with this condition and their family members to understand the underlying cause and potentially improve diagnosis and treatment.
Cincinnati, OhioAges Any age - NCT07651878RecruitingPhase 1
Vididencel immunotherapy for chronic myeloid leukemia with minimal residual disease
This study tests whether an experimental immune therapy called vididencel can help patients with chronic myeloid leukemia (CML) who have responded partially to standard tyrosine kinase inhibitor (TKI) drugs. The goal is to see if this therapy can further reduce the cancer cells remaining in their body.
BergenAges 18 years+ - NCT07652580Recruiting
Toxins, immunity, and B-cell lymphoma
This study looks at how exposure to toxins might affect your immune system if you have B-cell non-Hodgkin lymphoma. You'll provide blood and skin samples, plus have your genes sequenced, to help researchers find links between environmental exposures and lymphoma.
Bethesda, MarylandAges 4 years+ - NCT07652879RecruitingPhase 2
KCD drug combination for newly diagnosed POEMS syndrome
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
ShanghaiAges 18–75 - NCT07656909RecruitingPhase 2/Phase 3
Comparing low and high dose sirolimus with prednisolone for KHE with KMP
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
Chengdu, SichuanAges 1 day–18 years - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT07661095RecruitingPhase 1
Study of CRD3874-SI for relapsed or refractory AML
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
Basking Ridge, New JerseyAges 18 years+ - NCT07662369RecruitingPhase 1/Phase 2
A trial of special immune cells for viral infections after transplant
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
Shanghai, SHAges Any age - NCT07663253Recruiting
Isatuximab with VRd for newly diagnosed multiple myeloma patients not eligible for transplant
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07663864RecruitingPhase 1/Phase 2
Luspatercept for anemia after AML treatment
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
Guangzhou, GuangdongAges 18–60 - NCT07663903RecruitingPhase 3
New longer-lasting factor VIII for severe hemophilia A (on-demand use)
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
Tianjin, Tianjin MunicipalityAges 12–65
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,084 recruiting hematology studies from the U.S. registry right now, out of 7,742 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.